{"id":"NCT01135069","sponsor":"Spear Pharmaceuticals","briefTitle":"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo","officialTitle":"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2010-06-02","resultsPosted":"2014-10-16","lastUpdate":"2014-10-27"},"enrollment":480,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne"],"interventions":[{"type":"DRUG","name":"Tretinoin microsphere 0.1%","otherNames":[]},{"type":"DRUG","name":"Brand Retin-A Micro tretinoin microsphere gel 0.1%","otherNames":["Retin-A Micro"]},{"type":"DRUG","name":"placebo microsphere gel","otherNames":[]}],"arms":[{"label":"Generic","type":"ACTIVE_COMPARATOR"},{"label":"Brand","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.","primaryOutcome":{"measure":"Improvement in Acne","timeFrame":"12 weeks","effectByArm":[{"arm":"Generic","deltaMin":-74,"sd":0.05},{"arm":"Brand","deltaMin":-76,"sd":0.04},{"arm":"Placebo","deltaMin":-58,"sd":0.03}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":205},"commonTop":["Irritation"]}}